Free Trial

Prestige Consumer Healthcare (PBH) Stock Price, News & Analysis

+0.14 (+0.22%)
(As of 05/24/2024 07:00 PM ET)
Today's Range
50-Day Range
52-Week Range
235,000 shs
Average Volume
245,525 shs
Market Capitalization
$3.19 billion
P/E Ratio
Dividend Yield
Price Target

Prestige Consumer Healthcare MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
42.6% Upside
$91.25 Price Target
Short Interest
3.79% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.86mentions of Prestige Consumer Healthcare in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$12,112 Sold Last Quarter
Proj. Earnings Growth
From $4.41 to $4.74 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.37 out of 5 stars

Medical Sector

116th out of 921 stocks

Pharmaceutical Preparations Industry

46th out of 431 stocks

PBH stock logo

About Prestige Consumer Healthcare Stock (NYSE:PBH)

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

PBH Stock Price History

PBH Stock News Headlines

Prestige Consumer Q4 Earnings Miss, Operating Margin Falls
Prestige Consumer Healthcare Inc.
PBH Mar 2024 55.000 put
PBH Jul 2024 70.000 call
See More Headlines
Receive PBH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prestige Consumer Healthcare and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Personal Products
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
4 Analysts


Net Income
$209.34 million
Pretax Margin


Sales & Book Value

Annual Sales
$1.13 billion
Cash Flow
$4.98 per share
Book Value
$33.34 per share


Free Float
Market Cap
$3.19 billion
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

PBH Stock Analysis - Frequently Asked Questions

Should I buy or sell Prestige Consumer Healthcare stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prestige Consumer Healthcare in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PBH shares.
View PBH analyst ratings
or view top-rated stocks.

What is Prestige Consumer Healthcare's stock price target for 2024?

4 analysts have issued 12-month price targets for Prestige Consumer Healthcare's shares. Their PBH share price targets range from $65.00 to $117.00. On average, they expect the company's share price to reach $91.25 in the next year. This suggests a possible upside of 42.6% from the stock's current price.
View analysts price targets for PBH
or view top-rated stocks among Wall Street analysts.

How have PBH shares performed in 2024?

Prestige Consumer Healthcare's stock was trading at $61.22 on January 1st, 2024. Since then, PBH shares have increased by 4.5% and is now trading at $63.97.
View the best growth stocks for 2024 here

When is Prestige Consumer Healthcare's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024.
View our PBH earnings forecast

How were Prestige Consumer Healthcare's earnings last quarter?

Prestige Consumer Healthcare Inc. (NYSE:PBH) posted its quarterly earnings data on Tuesday, May, 14th. The company reported $1.02 earnings per share for the quarter, missing the consensus estimate of $1.14 by $0.12. The business had revenue of $277 million for the quarter, compared to analysts' expectations of $287.42 million. Prestige Consumer Healthcare had a net margin of 18.60% and a trailing twelve-month return on equity of 13.48%. The firm's revenue for the quarter was down 3.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.07 earnings per share.

What guidance has Prestige Consumer Healthcare issued on next quarter's earnings?

Prestige Consumer Healthcare updated its FY25 earnings guidance on Tuesday, May, 14th. The company provided earnings per share (EPS) guidance of $4.40-$4.46 for the period, compared to the consensus estimate of $4.65. The company issued revenue guidance of $1.125-$1.140 billion, compared to the consensus revenue estimate of $1.16 billion.

What is Ronald M. Lombardi's approval rating as Prestige Consumer Healthcare's CEO?

8 employees have rated Prestige Consumer Healthcare Chief Executive Officer Ronald M. Lombardi on Ronald M. Lombardi has an approval rating of 61% among the company's employees. This puts Ronald M. Lombardi in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Prestige Consumer Healthcare own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prestige Consumer Healthcare investors own include Pfizer (PFE), AbbVie (ABBV), Gilead Sciences (GILD), AT&T (T), Intel (INTC), ONEOK (OKE), Wells Fargo & Company (WFC), International Business Machines (IBM), Micron Technology (MU) and Teva Pharmaceutical Industries (TEVA).

Who are Prestige Consumer Healthcare's major shareholders?

Prestige Consumer Healthcare's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (11.57%), Ariel Investments LLC (5.16%), Allspring Global Investments Holdings LLC (2.11%), Allspring Global Investments Holdings LLC (2.11%), Westwood Holdings Group Inc. (1.83%) and Congress Asset Management Co. MA (1.54%). Insiders that own company stock include Mary Beth Fritz and Ronald M Lombardi.
View institutional ownership trends

How do I buy shares of Prestige Consumer Healthcare?

Shares of PBH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:PBH) was last updated on 5/27/2024 by Staff

From Our Partners